Published in Virology on May 25, 1998
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother (2004) 2.67
Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol (2001) 1.98
The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol (2007) 1.77
Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother (2001) 1.72
Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci U S A (2003) 1.58
Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J Virol (2007) 1.51
Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother (1998) 1.45
Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother (2002) 1.45
Antiviral activities of oral 1-O-hexadecylpropanediol-3-phosphoacyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother (2000) 1.21
Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci U S A (2005) 1.17
Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother (1999) 1.16
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother (2001) 1.09
Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method. J Virol (2005) 1.07
Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol (2002) 1.05
Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob Agents Chemother (2003) 1.04
Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. Antimicrob Agents Chemother (2003) 1.00
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother (2008) 0.99
Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections. J Virol (2000) 0.99
Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother (2000) 0.96
Experimental models and therapeutic approaches for HBV. Semin Immunopathol (2012) 0.95
Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother (2002) 0.94
The liver of woodchucks chronically infected with the woodchuck hepatitis virus contains foci of virus core antigen-negative hepatocytes with both altered and normal morphology. Virology (2006) 0.91
The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir. J Virol (2008) 0.90
Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol (2007) 0.88
Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int (2011) 0.87
Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother (2001) 0.86
Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob Agents Chemother (2000) 0.86
Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. J Virol (2002) 0.85
Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay. Antimicrob Agents Chemother (2003) 0.83
Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrob Agents Chemother (2001) 0.82
Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother (2004) 0.82
Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother (2009) 0.79
Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck. Hepat Res Treat (2010) 0.77
Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck. Med Microbiol Immunol (2014) 0.76
Emerging drugs for hepatitis B. Expert Opin Emerg Drugs (2007) 0.75
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer (2000) 4.89
Generation in vitro of deletions in the broad host range plasmid RK2 using phage Mu insertions and a restriction endonuclease. Gene (1976) 4.35
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology (1998) 4.14
Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med (1992) 4.02
Mortality rates in displaced and resident populations of central Somalia during 1992 famine. Lancet (1993) 3.84
Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med (1994) 3.61
Efficient duck hepatitis B virus production by an avian liver tumor cell line. J Virol (1990) 3.53
Evidence that a capped oligoribonucleotide is the primer for duck hepatitis B virus plus-strand DNA synthesis. J Virol (1986) 3.46
Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol (1994) 3.34
Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst (1999) 3.19
Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet (1997) 3.11
Changing patterns in epidemiology of Crohn's disease. Lancet (1974) 2.99
Initiation and termination of duck hepatitis B virus DNA synthesis during virus maturation. J Virol (1987) 2.89
Trends in self-reported use of mammograms (1989-1997) and Papanicolaou tests (1991-1997)--Behavioral Risk Factor Surveillance System. MMWR CDC Surveill Summ (1999) 2.77
In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology (1990) 2.76
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (2001) 2.72
Necropsy or autopsy? It's all about communication! Vet Pathol (2011) 2.59
Attitudes toward clinical trials among patients and the public. JAMA (1982) 2.53
Long-term therapy of chronic hepatitis B with lamivudine. Hepatology (2000) 2.49
Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer (1998) 2.48
Actinomycin D: inhibition of respiration and glycolysis. Science (1966) 2.47
Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J Virol (1994) 2.29
The National Breast and Cervical Cancer Early Detection Program: report on the first 4 years of mammography provided to medically underserved women. AJR Am J Roentgenol (1998) 2.24
Psychosocial status in chronic illness. A comparative analysis of six diagnostic groups. N Engl J Med (1984) 2.24
Some factors affecting cyclopropane acid formation in Escherichia coli. Biochem J (1965) 2.21
After the hospital episode. Lancet (1975) 2.11
An extracellular lipopolysaccharide-phospholipid-protein complex produced by Escherichia coli grown under lysine-limiting conditions. Biochem J (1967) 2.10
Clinical relevance of hepatitis B viral mutations. Hepatology (2000) 2.03
Physiologic and metabolic factors in the pathogenesis of neonatal enteric infections in calves. J Am Vet Med Assoc (1972) 2.00
Knowledge, attitudes, and screening practices among older men regarding prostate cancer. Am J Public Health (2000) 1.99
Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol (2001) 1.98
Vision screening for frail older people: a randomised trial. Br J Ophthalmol (2008) 1.93
Equine hepatic insufficiency. Vet Clin North Am (1973) 1.92
Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol (1997) 1.87
Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus. Virology (1988) 1.85
Septin: a factor in plasma that opsonizes lipopolysaccharide-bearing particles for recognition by CD14 on phagocytes. J Exp Med (1992) 1.85
Expression of the gene defect in X-linked agammaglobulinemia. N Engl J Med (1986) 1.80
Replication of DHBV genomes with mutations at the sites of initiation of minus- and plus-strand DNA synthesis. Virology (1992) 1.77
A clinical audit of patients on an orthopaedic waiting list for greater than two years. N Z Med J (1992) 1.76
Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol (2000) 1.73
Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother (2001) 1.72
The measurement of food and energy intake in man-an evaluation of some techniques. Am J Clin Nutr (1980) 1.68
Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 1.67
The Rand Health Insurance Study: a summary critique. Med Care (1987) 1.65
Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med (1998) 1.64
Requirement for HLA-DR+ accessory cells in natural killing of cytomegalovirus-infected fibroblasts. J Exp Med (1986) 1.63
Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study. J Clin Oncol (1999) 1.61
Human leukemia cell antigens: serologic characterization with xenoantisera. J Natl Cancer Inst (1974) 1.60
Gluttony. 1. An experimental study of overeating low- or high-protein diets. Am J Clin Nutr (1967) 1.57
Hepatitis delta virus RNA, protein synthesis and associated cytotoxicity in a stably transfected cell line. Virology (1990) 1.56
Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks. Virology (1996) 1.55
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology (2000) 1.55
The demographic and social characteristics of patients with Crohn's disease in the Nottingham area. Scand J Gastroenterol (1976) 1.54
Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol (1999) 1.52
Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type. J Natl Cancer Inst (1998) 1.50
Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol Oncol (1995) 1.49
Psychosocial correlates of survival in advanced malignant disease? N Engl J Med (1985) 1.48
Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol (2001) 1.48
Intestinal structure and function after small bowel by-pass in the rat. Clin Sci (1972) 1.47
Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside. Pediatr Infect Dis J (1989) 1.45
Mechanisms mediating renal secretion of organic anions and cations. Physiol Rev (1993) 1.45
Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. Am J Clin Nutr (1989) 1.42
Sensitivity and specificity of the neonatal brain-stem auditory evoked potential for hearing and language deficits in survivors of extracorporeal membrane oxygenation. J Pediatr (1997) 1.40
Multicystic ovarian tumor weighing 156 lbs: the second largest tumor in Texas. Tex Med (1997) 1.39
Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol (1994) 1.37
Artifacts caused by cell microinjection. Proc Natl Acad Sci U S A (1984) 1.35
Exclusion of superinfecting homologous virus by Sindbis virus-infected Aedes albopictus (mosquito) cells. J Virol (1986) 1.33
Gluttony. 2. Thermogenesis in overeating man. Am J Clin Nutr (1967) 1.33
P-glycoprotein-mediated secretion of a fluorescent cyclosporin analogue by teleost renal proximal tubules. Am J Physiol (1995) 1.30
New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection. Viral Immunol (1993) 1.30
Characterization of the antiviral effects of 2' carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology (1994) 1.29
Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum Mol Genet (1998) 1.29
The vascular architecture of the different forms of small intestinal villi in the rat (Rattus norvegicus). Scand J Gastroenterol (1969) 1.29
Resistance to slimming: adaptation or illusion? Lancet (1975) 1.27
Health habits and risk of cognitive impairment and dementia in old age: a prospective study on the effects of exercise, smoking and alcohol consumption. Aust N Z J Public Health (1998) 1.26
Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol (1999) 1.26
Varicella vaccine trials in healthy children. A summary of comparative and follow-up studies. Am J Dis Child (1984) 1.26
High-frequency jet ventilation in the early management of respiratory distress syndrome is associated with a greater risk for adverse outcomes. Pediatrics (1996) 1.26
Evidence that less-than-full-length pol gene products are functional in hepadnavirus DNA synthesis. J Virol (1991) 1.24
Characterization of age- and dose-related outcomes of duck hepatitis B virus infection. Virology (1998) 1.22
Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther (2001) 1.21
Cytoplasmic (but not nuclear) hepatitis B virus (HBV) core antigen reflects HBV DNA synthesis at the level of the infected hepatocyte. Intervirology (1985) 1.21
Lesions of the brachial plexus associated with fractures of the clavicle. Clin Orthop Relat Res (1969) 1.20
Fatty acid synthesis in Escherichia coli. Biochem J (1967) 1.20
Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. Adv Exp Med Biol (1999) 1.18
Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 1.18
A psychological analysis of cancer patients and their next-of-kin. Cancer (1985) 1.17
Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother (1999) 1.16